Correction: Sorafenib enhanced the function of myeloid‑derived suppressor cells in hepatocellular carcinoma by facilitating PPARα‑mediated fatty acid oxidation

Abstract

Correction: Mol Cancer 24, 34 (2025)

https://doi.org/10.1186/s12943-025–02238-5

Following publication of the original article [1], the author has requested the publication of an erratum to address the following issues stated below.

Figure 9B-9E. The authors believe that in the original article, the analysis of MDSCs (myeloid-derived suppressor cells) was conducted based on the CD45.1 and CD45.2 markers, where CD45.1 represents Ppara^+/+ WT and CD45.2 represents Ppara^-/- KO. However, in the original article, the author only labeled Ppara^+/+ and Ppara^-/- above the figure. This labeling method could potentially lead to misunderstandings, making readers mistakenly believe that these two experimental groups were derived from two independent mouse models, rather than a mixed chimeric model of the same recipient. To enhance the clarity of data analysis and avoid unnecessary misunderstandings, the author reanalyzed the data and implemented the following improvements: First, by gating CD11B+GR1+TGFB+ MDSC cells to ensure the selection of a functionally relevant MDSC population; then, analyzing based on the ratio of CD45.1 and CD45.2 to more clearly compare the responses of MDSCs from different sources to Sorafenib treatment within the same tumor microenvironment. Importantly, this optimization did not alter the study's conclusions, and the trends in the results remained consistent.

New Figure 9B-9E:

1. Li C, Xiong L, Yang Y, et al. Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation. Mol Cancer. 2025;24:34. https://doi.org/10.1186/s12943-025-02238-5.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Author notes

1. Chunxiao Li, Liting Xiong and Yuhan Yang contributed equally to this work.

Authors and Affiliations

1. Department of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China

   Chunxiao Li, Liting Xiong, Yuhan Yang, Ping Jiang, Junjie Wang, Mengyuan Li, Shuhua Wei, Suqing Tian, Yuexuan Wang, Mi Zhang & Jie Tang

Authors

1. Chunxiao LiView author publications

   You can also search for this author inPubMed Google Scholar

2. Liting XiongView author publications

   You can also search for this author inPubMed Google Scholar

3. Yuhan YangView author publications

   You can also search for this author inPubMed Google Scholar

4. Ping JiangView author publications

   You can also search for this author inPubMed Google Scholar

5. Junjie WangView author publications

   You can also search for this author inPubMed Google Scholar

6. Mengyuan LiView author publications

   You can also search for this author inPubMed Google Scholar

7. Shuhua WeiView author publications

   You can also search for this author inPubMed Google Scholar

8. Suqing TianView author publications

   You can also search for this author inPubMed Google Scholar

9. Yuexuan WangView author publications

   You can also search for this author inPubMed Google Scholar

10. Mi ZhangView author publications

    You can also search for this author inPubMed Google Scholar

11. Jie TangView author publications

    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence to Chunxiao Li, Ping Jiang or Junjie Wang.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Li, C., Xiong, L., Yang, Y. et al. Correction: Sorafenib enhanced the function of myeloid‑derived suppressor cells in hepatocellular carcinoma by facilitating PPARα‑mediated fatty acid oxidation. Mol Cancer 24, 91 (2025). https://doi.org/10.1186/s12943-025-02303-z

Download citation

• Published: 21 March 2025

• DOI: https://doi.org/10.1186/s12943-025-02303-z

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative